

# Exome sequencing of lymphomas from three dog breeds reveals somatic mutation patterns reflecting genetic background

Ingegerd Elvers,<sup>1,2</sup> Jason Turner-Maier,<sup>1</sup> Ross Swofford,<sup>1</sup> Michele Koltookian,<sup>1</sup> Jeremy Johnson,<sup>1</sup> Chip Stewart,<sup>1</sup> Cheng-Zhong Zhang,<sup>1,3</sup> Steven E. Schumacher,<sup>1,3</sup> Rameen Beroukhi,<sup>1,3</sup> Mara Rosenberg,<sup>1</sup> Rachael Thomas,<sup>4</sup> Evan Mauceli,<sup>1,9</sup> Gad Getz,<sup>1,5,6</sup> Federica Di Palma,<sup>1,10</sup> Jaime F. Modiano,<sup>7</sup> Matthew Breen,<sup>4,8</sup> Kerstin Lindblad-Toh,<sup>1,2</sup> and Jessica Alföldi<sup>1</sup>

<sup>1</sup>Broad Institute, Cambridge, Massachusetts 02142, USA; <sup>2</sup>Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala SE 751 23, Sweden; <sup>3</sup>Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; <sup>4</sup>North Carolina State University, Raleigh, North Carolina 27695, USA; <sup>5</sup>Harvard Medical School, Boston, Massachusetts 02115, USA; <sup>6</sup>Massachusetts General Hospital, Boston, Massachusetts 02114, USA; <sup>7</sup>Animal Cancer Care and Research Program, College of Veterinary Medicine, and Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455, USA; <sup>8</sup>University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27514, USA

Lymphoma is the most common hematological malignancy in developed countries. Outcome is strongly determined by molecular subtype, reflecting a need for new and improved treatment options. Dogs spontaneously develop lymphoma, and the predisposition of certain breeds indicates genetic risk factors. Using the dog breed structure, we selected three lymphoma predisposed breeds developing primarily T-cell (boxer), primarily B-cell (cocker spaniel), and with equal distribution of B- and T-cell lymphoma (golden retriever), respectively. We investigated the somatic mutations in B- and T-cell lymphomas from these breeds by exome sequencing of tumor and normal pairs. Strong similarities were evident between B-cell lymphomas from golden retrievers and cocker spaniels, with recurrent mutations in *TRAF3-MAP3K14* (28% of all cases), *FBXW7* (25%), and *POT1* (17%). The *FBXW7* mutations recurrently occur in a specific codon; the corresponding codon is recurrently mutated in human cancer. In contrast, T-cell lymphomas from the predisposed breeds, boxers and golden retrievers, show little overlap in their mutation pattern, sharing only one of their 15 most recurrently mutated genes. Boxers, which develop aggressive T-cell lymphomas, are typically mutated in the PTEN-mTOR pathway. T-cell lymphomas in golden retrievers are often less aggressive, and their tumors typically showed mutations in genes involved in cellular metabolism. We identify genes with known involvement in human lymphoma and leukemia, genes implicated in other human cancers, as well as novel genes that could allow new therapeutic options.

[Supplemental material is available for this article.]

Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous, aggressive form of non-Hodgkin lymphoma (NHL) and the most prevalent form of B-cell NHL in people. Approximately 30,000 DLBCL cases are diagnosed each year in the United States, of which only half are curable (Abramson and Shipp 2005). Molecular subclassifications of DLBCL are highly predictive of treatment outcome (Alizadeh et al. 2000). NHL can also arise from T cells, making up 10%–15% of all NHL cases. T-cell lymphomas are highly heterogeneous and several subtypes exist (Evens and Gartenhaus 2003; Iqbal et al. 2010).

Dogs have previously been proven useful in determining predisposing genetic markers for human diseases due to the breed

structure caused by artificial breeding for phenotypic factors (Dodman et al. 2010; Wilbe et al. 2010; Shearin et al. 2012; Karlsson et al. 2013; Tang et al. 2014). A recent lymphoma study in dogs identified a gene (*TRAF3*) as being commonly mutated in both dog and human B-cell lymphomas (Bushell et al. 2015). However, this study did not separate canine tumors based on breed, preventing the discovery of somatic mutations reflecting genetic background. Since dog breeds represent genetic isolates, comparing dog breeds with differential predispositions to cancer can indicate the role of the genetic background and allow for better detection of mutations influenced by that genetic background. In dogs, malignant lymphoma is the most common tumor treated with chemotherapy, affecting dogs of all ages and breeds (Valli et al. 2013); however, the high rate of lymphoma in certain breeds and preferential cells of origin among different breeds indicates genetic risk factors (Modiano et al. 2005).

**Present addresses:** <sup>9</sup>Parabase Genomics, MA, USA; <sup>10</sup>The Genome Analysis Centre, UK

**Corresponding authors:** [ielvers@broadinstitute.org](mailto:ielvers@broadinstitute.org), [kersli@broadinstitute.org](mailto:kersli@broadinstitute.org)

Article published online before print. Article, supplemental material, and publication date are at <http://www.genome.org/cgi/doi/10.1101/gr.194449.115>. Freely available online through the *Genome Research* Open Access option.

© 2015 Elvers et al. This article, published in *Genome Research*, is available under a Creative Commons License (Attribution 4.0 International), as described at <http://creativecommons.org/licenses/by/4.0/>.

Approximately 70% of all canine lymphomas arise from B cells (Modiano et al. 2005; Ponce et al. 2010). The most common form of canine B-cell lymphoma is the clinical and histological equivalent of human DLBCL (Vail and MacEwen 2000; Modiano et al. 2005; Valli et al. 2011; Ito et al. 2014). As in humans, the CHOP-based chemotherapy protocols are the most effective treatment for canine B-cell lymphomas. T-cell lymphomas are less common in dogs, and the most aggressive types have a higher risk of relapse and early death (Ruslander et al. 1997; Dobson et al. 2001). Many T-cell lymphomas also have a low long-term survival frequency in humans.

Exome sequencing efforts in human lymphomas have shown that certain mutations are specific for lymphoma subtypes or shared between only a few subtypes (Zhang et al. 2014). For example, DLBCL typically have mutations affecting B-cell receptor signaling or subunits, e.g., *CD79A/B*, and in histone modifiers like *EZH2* and *MLL2*, *PRDM1*, *TP53*, *CARD11*, and *MYD88* (Lenz et al. 2008; Davis et al. 2010; Mandelbaum et al. 2010; Morin et al. 2010; Ngo et al. 2011; Lohr et al. 2012). *MYD88* is also recurrently mutated in other B-cell lymphomas like primary central nervous system lymphoma (PCNSL) (Gonzalez-Aguilar et al. 2012), and *MLL2* and *TP53* mutations have been reported for mantle cell lymphoma (MCL) (Zhang et al. 2014). The two main human DLBCL subtypes—activated B cell (ABC) and germinal center B cell (GCB)—which can be distinguished based on differential gene expression and prognosis (Alizadeh et al. 2000), also have unique recurrent mutations. ABC DLBCLs are characterized by mutations in B-cell differentiation genes and often show constitutive activation of NF- $\kappa$ B signaling, whereas *BCL2* and *MYC* translocations are characteristic of GCB DLBCLs (summarized in Pasqualucci et al. 2011b). Canine B-cell lymphomas can also be separated into germinal and post-germinal center types using gene expression data, sharing pathways with their human counterparts (Richards et al. 2013), although more studies are needed to fully elucidate this. T-cell lymphomas are much less studied compared with B-cell lymphomas, particularly DLBCL.


The treatment outcome of canine lymphoma is predictive of the human response to the same treatment (Honigberg et al. 2010; Marconato et al. 2013; London et al. 2014), and canine clinical trials, although highly regulated, are easier to complete compared with human trials. Hence, a better understanding of canine lymphoma offers great potential to accelerate development of new treatments for human patients. Here, we have compared the somatic mutations of B- and T-cell canine lymphoma in three dog breeds with different lymphoma immunophenotype predispositions. The identified breed-specific patterns are a good opportunity to study interventions targeting the significant mutations.

## Results

### General mutation load and significantly mutated genes

To allow detection of typical B- and T-cell lymphoma tumor mutations in different genetic backgrounds, samples were collected from three dog breeds predisposed

to different lymphoma subtypes (Modiano et al. 2005). This is the largest canine lymphoma exome sequencing effort to date. The average lymphoma incidence has been estimated as 20–100 cases per 100,000 dogs (Ito et al. 2014). Golden retrievers in the United States are predisposed to both B- and T-cell lymphoma, with 13% developing lymphoma, and >60% developing cancer generally (Glickman et al. 2000). B- and T-cell lymphoma is equally common in this breed, indicating that they are relatively more predisposed to T-cell lymphoma, which normally makes up one-third of the lymphoma cases (Modiano et al. 2005). Boxers also show lymphoma predisposition (Modiano et al. 2005), and ~90% of their lymphomas originate from T cells (Modiano et al. 2005; Pastor et al. 2009). For a breed typically developing B-cell lymphomas (relative frequency about 9:1 for B:T-cell), cocker spaniels were chosen (Modiano et al. 2005). The differential predisposition to lymphoma arising from different cell types reflects the homogeneous genetic backgrounds of dog breeds, different among breeds but relatively homogeneous within each breed. All three breeds chosen were created independently ~200 yr ago, and are not related beyond the species level (Vaysse et al. 2011). The number of sequenced samples is shown in Figure 1; 64 B-cell lymphomas (54 from golden retriever [Gr B-cell] and 10 from cocker spaniel [Cs B-cell]) and 41 T-cell lymphomas (25 from golden retriever [Gr T-cell] and 16 from boxer [Bx T-cell]). The difference in sample group sizes reflects both the popularity of and the lymphoma frequency in each breed. The analysis pipeline is outlined in Figure 1. Matched tumor and normal samples were collected, and their exomes were captured via a Roche custom designed canine exome (50 Mb) followed by sequencing by Illumina (average depth normal 72 $\times$ , tumor 93 $\times$ ). MuTect (Cibulskis et al. 2013) and IndelLocator (<http://www.broadinstitute.org/cancer/cga/indelocator>) were used to call variants and identify somatic mutations, which were then annotated with SnpEff (Cingolani et al. 2012). On average, 476 somatic mutations, of which 18 were nonsilent protein-coding mutations, were identified in each sample. T-cell lymphomas had a higher average load of nonsilent protein-coding mutations compared to B-cell lymphomas (23 versus 15 per sample,  $P_{t-test} = 2.3 \times 10^{-3}$ ) (Fig. 1). The overall pattern of somatic mutations was similar across the breed and lymphoma immunophenotype groups (Supplemental Fig. S1), but golden



**Figure 1.** Analysis pipeline and mutation number overview. (A) Sample numbers and average mutations per breed and immunophenotype are indicated. (B) Exome libraries were sequenced and variants were called with MuTect, a caller adapted for cancer data, and IndelLocator. Somatic variants were annotated using SnpEff. MuSIC was used for identification of significantly mutated genes.

retrievers have on average 33% fewer total mutations compared to the other two breeds ( $p_{t\text{-test}} = 2.8 \times 10^{-6}$ ) (Fig. 1). The number of somatic mutations did not increase with sequencing depth (Supplemental Fig. S2), indicating that the sequencing was deep enough to comprehensively identify mutations and use these for comparison between breeds and tumor types.

The nonsilent coding mutations, around 18 per sample (Fig. 1; Supplemental Table S1), were used to identify significantly mutated genes using the Genome MuSiC tool (Dees et al. 2012). The number of significantly mutated genes largely reflects the number of input samples. The vast majority (93%, 87 of 94) of significantly somatically mutated genes were significantly mutated in only one lymphoma immunophenotype group (Fig. 2). The top most significantly mutated genes in B-cell lymphomas are *POT1*, *FBXW7*, and *TRAF3* (Table 1; Supplemental Table S2). Other B-cell lymphoma defining genes include the *FAM90A1* uncharacterized protein, the tumor suppressor *TP53*, the RNA helicase *DDX3X*, proteasome subunit *PSMA1*, proline-rich nuclear receptor coactivator 1 (*PNRC1*), SET-domain containing 2 (*SETD2*), and mitogen-activated protein kinase kinase 14 (*MAP3K14*). The large majority of those have high protein identity with their human counterparts (Supplemental Table S3A). Notably, *TRAF3* and *MAP3K14* (*NIK*) act in the same complex in the alternative NF- $\kappa$ B pathway. Both have been reported as mutated in human classical Hodgkin lymphoma (Otto et al. 2012) as well as mantle cell lymphoma, where *MAP3K14* was recently reported as a new therapeutic target (Rahal et al. 2014). NF- $\kappa$ B pathway deregulation is also a feature of many DLBCL tumors (Compagno et al. 2009). *DDX3X* has been reported to be mutated in Burkitt's lymphoma (Richter et al. 2012). *SETD2* is a histone methyltransferase. Several histone methyltransferases (primarily *MLL2*, *EZH2*) and acetyltransferases (typically *CREBBP*, *EP300*) have been implicated in human lymphoma (Morin et al. 2011; Pasqualucci et al. 2011a,b). As described for human DLBCL (Pasqualucci et al. 2011b), mutations in these genes are largely mutually exclusive among the studied B-cell lymphomas (Supplemental Fig. S3). In the T-cell lymphoma cohort, the most significantly mutated genes (Table 2) are *SATB1* homeobox 1 (*SATB1*), followed by *TBC1D26* (uncharacterized protein), proteasome subunit *PSMA1*, cytochrome c oxidase subunit VIII (*COX8A*), and tumor suppressor *PTEN*. About half of the most significantly mutated genes in this study have been implicated in hu-


man lymphoma, but there are also several hits that have not previously been reported in human cancer studies, such as genes from the *NLRP* family, with a role in innate immunity. In addition, a smaller fraction of the significantly mutated genes, such as *PSMA1* and *KPNA2*, have not been reported in human lymphoma but have been reported in other human cancers.

### B-cell tumor mutations are more uniform than T-cell tumor mutations

Only seven genes (7%) were significantly (as determined by MuSiC analysis) mutated in both lymphoma immunophenotype groups, such as the proteasome subunit gene *PSMA1*, and the genes encoding the two uncharacterized proteins *FAM90A1* and *TBC1D26*. With few exceptions, most genes are significantly mutated in either B- or T-cell lymphoma and not in both (Fig. 2; Supplemental Table S2).

B-cell lymphoma-defining genes show striking similarities between the two predisposed breeds. Of all significantly mutated genes in cocker spaniel B-cell lymphomas, 62.5% (5 of 8) are also among the 15 most significantly mutated golden retriever B-cell lymphoma genes (Fig. 2). Of the four top significant genes, two are shared. In contrast, among T-cell lymphomas, the significantly mutated genes are most often confined to only one breed (Table 2).

The effects of these mutations were estimated using Ingenuity Pathway Analysis (IPA; <http://www.ingenuity.com>) on the significantly mutated genes for each breed and tumor type. As the majority of significantly mutated canine genes have high protein identity with their human orthologs, pathways are expected to be conserved between canine and human. As expected from their differential sharing of typical mutations, the canonical pathways altered are highly overlapping between cocker spaniel and golden retriever B-cell lymphomas, and they are very different between boxer and golden retriever T-cell lymphomas. Seventy-five percent (34 of 46) of all canonical pathways altered by the genes that are significantly mutated in Cs B-cell lymphomas are also implicated for the Gr B-cell lymphoma tumors (Table 3; Supplemental Table S4). In contrast, only 15% of the Bx T-cell lymphoma canonical pathways are also implicated in Gr T-cell lymphoma tumors (Table 4; Supplemental Table S5). A similar pattern is seen when functional annotation charts generated from top significantly



**Figure 2.** Overlap of significantly mutated genes. (A) The two B-cell lymphoma predisposed breeds share some of their most significantly mutated genes. (B) The two T-cell lymphoma predisposed breeds do not share any top significantly mutated genes. (C) There is some overlap in significantly mutated genes between the all B-cell lymphomas compared with the all T-cell lymphomas.

**Table 1.** Top significantly mutated genes in B-cell lymphoma and their mutation frequency

Gene ID	P-value CT	FDR CT	Cs B-cell (n = 10) (%)	Gr B-cell (n = 54) (%)	All B-cell (n = 64) (%)	All T-cell (n = 41) (%)
Cocker spaniel						
<i>FAM90A1</i>	$3.47 \times 10^{-9}$	$8.51 \times 10^{-5}$	30.0	13.0	15.6	7.3
<i>DDX3X</i>	$1.72 \times 10^{-8}$	$2.10 \times 10^{-4}$	30.0	7.4	10.9	0
<i>TRAF3</i>	$6.44 \times 10^{-8}$	$5.26 \times 10^{-4}$	30.0	18.5	20.3	0
<i>MITF</i>	$1.70 \times 10^{-7}$	$1.04 \times 10^{-3}$	20.0	0	3.1	0
<i>PSMA1</i>	$4.11 \times 10^{-7}$	$2.02 \times 10^{-3}$	20.0	5.6	7.8	9.8
<i>MYC</i>	$1.46 \times 10^{-6}$	$5.98 \times 10^{-3}$	20.0	0	3.1	0
<i>GRIFIN</i>	$6.07 \times 10^{-6}$	$2.13 \times 10^{-2}$	20.0	0	3.1	4.9
<i>POT1</i>	$8.15 \times 10^{-6}$	$2.22 \times 10^{-2}$	20.0	16.7	17.2	0
Golden retriever						
<i>FBXW7</i>	$0.00 \times 10^{+0}$	$0.00 \times 10^{+0}$	10.0	27.8	25.0	4.9
<i>POT1</i>	$1.10 \times 10^{+22}$	$1.34 \times 10^{-18}$	20.0	16.7	17.2	0
<i>TRAF3</i>	$1.56 \times 10^{-19}$	$1.28 \times 10^{-15}$	30.0	18.5	20.3	0
<i>FAM90A1</i>	$2.36 \times 10^{-18}$	$1.45 \times 10^{-14}$	30.0	13.0	15.6	7.3
<i>ENSCAFG00000031638</i>	$5.30 \times 10^{-18}$	$2.60 \times 10^{-14}$	10.0	13.0	12.5	9.8
<i>TP53</i>	$2.25 \times 10^{-17}$	$9.18 \times 10^{-14}$	20.0	14.8	15.6	4.9
<i>PNRC1</i>	$1.07 \times 10^{-12}$	$3.76 \times 10^{-9}$	0	9.3	7.8	4.9
<i>FKBP3</i>	$1.26 \times 10^{-9}$	$3.32 \times 10^{-6}$	0	5.6	4.7	0.0
<i>TBC1D26</i>	$1.13 \times 10^{-9}$	$3.32 \times 10^{-6}$	10.0	7.4	6.3	14.6
<i>RPL23A</i>	$1.35 \times 10^{-9}$	$3.32 \times 10^{-6}$	10.0	3.7	6.3	4.9
<i>FAM90A1</i>	$6.43 \times 10^{-9}$	$1.43 \times 10^{-5}$	30.0	13.0	15.6	7.3
<i>SOCS2</i>	$7.75 \times 10^{-9}$	$1.58 \times 10^{-5}$	0	5.6	4.7	2.4
<i>PSMA1</i>	$1.21 \times 10^{-8}$	$2.28 \times 10^{-5}$	20.0	5.6	7.8	9.8
<i>DDX3X</i>	$1.99 \times 10^{-8}$	$3.48 \times 10^{-5}$	30.0	7.4	10.9	0
<i>SETD2</i>	$3.33 \times 10^{-8}$	$5.44 \times 10^{-5}$	20.0	11.1	12.5	2.4

mutated genes using DAVID (Huang da et al. 2009a,b) are compared.

Somatic copy number alterations (SCNAs) estimated from the exome sequencing data confirm the differences between B- and T-cell lymphomas. The most significant alterations are deletions in part of the T-cell receptor (*TCR*), which are typically seen in lymphomas originating from T cells ( $P_{t\text{-test}} = 1.7 \times 10^{-7}$ ), and deletions in two immunoglobulin genes, more commonly seen in lymphomas originating from B cells (Table 5; Supplemen-

tal Table S6). These deletions are likely not a cancer-driven alteration, but rather *TCR* and immunoglobulin gene diversity reflecting the tumor cell of origin. In addition, the detected SCNAs (Supplemental Fig. S4) show overlap with a few of the recurrently mutated genes, such as *KLRK1*, a member of the killer cell lectin-like receptor subfamily K, and *PKD1*, which encodes a polycystin protein involved in cell-cell/matrix interactions and with a role in cell migration and invasion in human osteosarcoma (Onishi et al. 2012). The SCNAs are seen in both B- and T-cell

**Table 2.** Top significantly mutated genes in T-cell lymphoma and their mutation frequency

Gene ID	P-value CT	FDR CT	Bx T-cell (n = 16) (%)	Gr T-cell (n = 25) (%)	All T-cell (n = 41) (%)	All B-cell (n = 64) (%)
Boxer						
<i>PTEN</i>	$2.52 \times 10^{-11}$	$6.19 \times 10^{-7}$	25.0	0	9.8	0
<i>SATB1</i>	$3.61 \times 10^{-10}$	$4.42 \times 10^{-6}$	25.0	12.0	17.1	0
<i>MAP2K1</i>	$2.28 \times 10^{-6}$	$1.86 \times 10^{-2}$	12.5	0	4.9	0
<i>EEF1A1</i>	$6.40 \times 10^{-6}$	$3.26 \times 10^{-2}$	0	12.0	1.6	7.3
<i>NLRP14</i>	$6.64 \times 10^{-6}$	$3.26 \times 10^{-2}$	12.5	0	4.9	1.6
<i>KCND2</i>	$1.22 \times 10^{-5}$	$4.99 \times 10^{-2}$	12.5	0	4.9	1.6
Golden retriever						
<i>PSMA1</i>	$4.86 \times 10^{-13}$	$1.19 \times 10^{-8}$	6.3	16.0	9.8	7.8
<i>COX8A</i>	$1.51 \times 10^{-11}$	$1.85 \times 10^{-7}$	0	12.0	7.3	0
<i>LTA4H</i>	$1.95 \times 10^{-9}$	$1.19 \times 10^{-5}$	0	16.0	9.8	1.6
<i>TBC1D26</i>	$1.57 \times 10^{-9}$	$1.19 \times 10^{-5}$	6.3	20.0	14.6	6.3
<i>ZNF706</i>	$1.77 \times 10^{-8}$	$8.69 \times 10^{-5}$	0	8.0	4.9	0
<i>ATP5H</i>	$7.49 \times 10^{-8}$	$3.06 \times 10^{-4}$	0	8.0	4.9	3.1
<i>ENSCAFG00000031638</i>	$1.45 \times 10^{-7}$	$5.09 \times 10^{-4}$	6.3	12.0	9.8	12.5
<i>PTPN6</i>	$3.23 \times 10^{-7}$	$9.91 \times 10^{-4}$	0	12.0	7.3	0
<i>NLRP5</i>	$3.68 \times 10^{-7}$	$1.00 \times 10^{-3}$	0	12.0	7.3	1.6
<i>GLUD2</i>	$6.04 \times 10^{-7}$	$1.48 \times 10^{-3}$	0	12.0	7.3	3.1
<i>RPL11</i>	$6.92 \times 10^{-7}$	$1.54 \times 10^{-3}$	0	8.0	4.9	0
<i>SATB1</i>	$3.44 \times 10^{-6}$	$7.04 \times 10^{-3}$	25.0	12.0	17.1	0
<i>RPL23A</i>	$4.08 \times 10^{-6}$	$7.70 \times 10^{-3}$	0	8.0	4.9	6.3
<i>KRTAP10-6</i>	$5.13 \times 10^{-6}$	$8.98 \times 10^{-3}$	0	12.0	7.3	0
<i>MAGEC2</i>	$6.38 \times 10^{-6}$	$1.04 \times 10^{-2}$	0	8.0	4.9	0

**Table 3.** Canonical pathways ( $P < 0.01$ ) suggested by IPA for significantly mutated genes from B-cell lymphomas from cocker spaniel, golden retriever, and both breeds combined

	P-value	Genes
Cocker spaniel		
Small cell lung cancer signaling	$2.57 \times 10^{-4}$	MYC, TRAF3
Telomerase signaling	$5.01 \times 10^{-4}$	MYC, POT1
Role of macrophages, fibroblasts and endothelial cells in rheumatoid arthritis	$4.37 \times 10^{-3}$	MYC, TRAF3
Telomere extension by telomerase	$5.25 \times 10^{-3}$	POT1
Polyamine regulation in colon cancer	$7.59 \times 10^{-3}$	MYC
Estrogen-mediated S-phase entry	$8.32 \times 10^{-3}$	MYC
Golden retriever		
NGF signaling	$1.91 \times 10^{-3}$	TP53, MAP3K14, NTRK1
TWEAK signaling	$2.75 \times 10^{-3}$	MAP3K14, TRAF3
APRIL-mediated signaling	$3.39 \times 10^{-3}$	MAP3K14, TRAF3
Role of PKR in interferon induction and antiviral response	$3.80 \times 10^{-3}$	TP53, TRAF3
B-cell activating factor signaling	$3.80 \times 10^{-3}$	MAP3K14, TRAF3
Thyroid cancer signaling	$3.80 \times 10^{-3}$	TP53, NTRK1
Glutamate biosynthesis II	$4.57 \times 10^{-3}$	GLUD2
Glutamate degradation X	$4.57 \times 10^{-3}$	GLUD2
Role of Oct4 in mammalian embryonic stem cell pluripotency	$5.01 \times 10^{-3}$	TP53, PHC3
Lymphotoxin $\beta$ receptor signaling	$6.76 \times 10^{-3}$	MAP3K14, TRAF3
NF- $\kappa$ B signaling	$7.24 \times 10^{-3}$	MAP3K14, TRAF3, NTRK1
Induction of apoptosis by HIV1	$8.32 \times 10^{-3}$	TP53, MAP3K14
CD40 signaling	$9.77 \times 10^{-3}$	MAP3K14, TRAF3
Cocker spaniel + golden retriever		
Thyroid cancer signaling	$1.17 \times 10^{-4}$	TP53, MYC, NTRK1
Small cell lung cancer signaling	$6.46 \times 10^{-4}$	TP53, MYC, TRAF3
STAT3 pathway	$7.08 \times 10^{-4}$	MYC, NTRK1, SOCS2
Telomerase signaling	$1.70 \times 10^{-3}$	TP53, MYC, POT1
NGF signaling	$2.14 \times 10^{-3}$	TP53, MAP3K14, NTRK1
TWEAK signaling	$2.95 \times 10^{-3}$	MAP3K14, TRAF3
APRIL-mediated signaling	$3.72 \times 10^{-3}$	MAP3K14, TRAF3
Role of PKR in interferon induction and antiviral response	$4.07 \times 10^{-3}$	TP53, TRAF3
B-cell activating factor signaling	$4.07 \times 10^{-3}$	MAP3K14, TRAF3
Melanoma signaling	$4.57 \times 10^{-3}$	TP53, MITF

lymphomas, although these two genes are only significantly mutated in B-cell lymphomas.

#### B-cell lymphoma defining pathways point to the importance of telomerase and autoimmunity

The pathways affected by typical B-cell lymphoma tumor mutations highlight the importance of telomerase and proliferation signaling for successful tumor development, as well as pathways involved in autoimmunity. The top network estimated by IPA for the combined B-cell lymphoma data set is "Cancer, Hematological Disease, Immunological Disease" (Supplemental Table S7). The canonical pathways identified for the two B-cell lymphoma data sets, when analyzed separately as well as together, include pathways for specific cancers, telomerase signaling pathways, and pathways associated with proliferation/apoptosis and autoimmune disorders, such as TWEAK signaling, APRIL-mediated signaling, and the STAT3 pathway (Table 3; Supplemental Table S4). Cell death and immunity (CD40L and TNF receptor and ligand

signaling) were also reported when the top significantly mutated genes were functionally annotated using DAVID (Huang da et al. 2009a,b) (Supplemental Table S8).

POT1, the most significantly somatically mutated gene in the Gr and Cs B-cell lymphomas combined, encodes a protein important for telomere maintenance, and mutations in this gene predispose to several types of cancer in human (Robles-Espinoza et al. 2014; Shi et al. 2014). The gene is also recurrently mutated, lost, or differentially regulated in human cancers, including lymphoma (Bellon et al. 2006; Vega et al. 2008).

The second most significantly mutated gene among all B-cell lymphomas combined is the most commonly mutated gene among Gr B-cell lymphomas alone. This gene encodes the E3 ubiquitin ligase FBXW7, which targets cyclin E for degradation (Koepp et al. 2001) and controls the stability of MYC (Yada et al. 2004). FBXW7 has been shown to be recurrently mutated at two amino acid positions in human cancers (Lawrence et al. 2014). As shown in Figure 3, 41% of all FBXW7 mutations in our lymphomas occur at the corresponding codon as one of those positions (canine R470, equivalent to human R465) (see Supplemental Table S3B). Notably, FBXW7 is much more recurrently mutated in Gr B-cell than Cs B-cell lymphomas, and it is also mutated in a few Gr T-cell lymphomas but none of the studied Bx T-cell lymphomas.

**Table 4.** Top canonical pathways suggested by IPA for significantly mutated genes from T-cell lymphomas from boxer and golden retriever

Ingenuity canonical pathways	P-value	Ratio	Genes
Boxer			
Melanoma signaling	$6.31 \times 10^{-5}$	0.0476	MAP2K1, PTEN
Endometrial cancer signaling	$9.77 \times 10^{-5}$	0.0385	MAP2K1, PTEN
ERBB2-ERBB3 signaling	$1.17 \times 10^{-4}$	0.0351	MAP2K1, PTEN
IL-17A signaling in airway cells	$1.48 \times 10^{-4}$	0.0312	MAP2K1, PTEN
Prostate cancer signaling	$2.45 \times 10^{-4}$	0.0244	MAP2K1, PTEN
FAK signaling	$2.75 \times 10^{-4}$	0.023	MAP2K1, PTEN
Neuregulin signaling	$2.82 \times 10^{-4}$	0.0227	MAP2K1, PTEN
Glioma signaling	$3.31 \times 10^{-4}$	0.0211	MAP2K1, PTEN
PTEN signaling	$5.01 \times 10^{-4}$	0.0169	MAP2K1, PTEN
PI3K/AKT signaling	$5.50 \times 10^{-4}$	0.0163	MAP2K1, PTEN
PI3K signaling in B lymphocytes	$5.89 \times 10^{-4}$	0.0156	MAP2K1, PTEN
Ovarian cancer signaling	$6.17 \times 10^{-4}$	0.0153	MAP2K1, PTEN
Insulin receptor signaling	$6.46 \times 10^{-4}$	0.0149	MAP2K1, PTEN
Glioblastoma multiforme signaling	$7.76 \times 10^{-4}$	0.0137	MAP2K1, PTEN
RAR activation	$1.12 \times 10^{-3}$	0.0114	MAP2K1, PTEN
Golden retriever			
Glutamate biosynthesis II	$1.70 \times 10^{-3}$	0.5	GLUD2
Glutamate degradation X	$1.70 \times 10^{-3}$	0.5	GLUD2
Oxidative phosphorylation	$3.80 \times 10^{-3}$	0.0183	ATP5H, COX8A
Arginine biosynthesis IV	$5.01 \times 10^{-3}$	0.167	GLUD2
Mitochondrial dysfunction	$8.91 \times 10^{-3}$	0.0117	ATP5H, COX8A

**Table 5.** Top somatic copy number alterations

SCNA descriptor <sup>a</sup>	Q-values after peak arbitration	Peak limits	Comment	B versus T, t-test (two-tail, type 2)
8q11.2 (deletion)	$2.98 \times 10^{-19}$	Chr8:2869427–2882658	<i>TCR</i>	$1.72 \times 10^{-7}$
8q33.3 (deletion)	$8.14 \times 10^{-15}$	Chr8:72990670–73028555	Part of <i>IGH</i> gene	$4.51 \times 10^{-2}$
26q23 (deletion)	$3.52 \times 10^{-13}$	Chr26:27585064–27602759	Part of <i>IGL</i> gene	$5.51 \times 10^{-2}$
27q22.1 (deletion)	$1.01 \times 10^{-7}$	Chr27:35640457–35649322	<i>KLRK1</i>	
11q15 (deletion)	$1.81 \times 10^{-7}$	Chr11:41264940–41305867		
16q12 (deletion)	$3.15 \times 10^{-7}$	Chr16:6774247–6793678		
13q21.1 (amplification)	$7.77 \times 10^{-6}$	Chr13:37810498–37816495		
26q23 (amplification)	$2.48 \times 10^{-5}$	Chr26:27303323–27354974		
18q12 (deletion)	$8.94 \times 10^{-5}$	Chr18:11622188–11700181		
6q21.3 (amplification)	$2.56 \times 10^{-4}$	Chr6:38834153–38845543	<i>PKD1</i>	
8q33.3 (amplification)	$2.70 \times 10^{-4}$	Chr8:72851488–72862981		
24q25 (amplification)	$6.28 \times 10^{-4}$	Chr24:47029779–47110403		
24q25 (deletion)	$8.95 \times 10^{-4}$	Chr24:44492687–44530980		
20q17 (amplification)	$1.25 \times 10^{-3}$	Chr20:57364803–57378205		
18q22.1 (amplification)	$1.69 \times 10^{-3}$	Chr18:25723457–25727487		
31q15.1 (amplification)	$1.69 \times 10^{-3}$	Chr31:29912719–30091933		
10q14 (amplification)	$1.74 \times 10^{-3}$	Chr10:17021157–17029882		
28q18 (amplification)	$1.74 \times 10^{-3}$	Chr28:40745394–40855815		
32q11.2 (deletion)	$1.95 \times 10^{-3}$	Chr32:13499741–14258756		

<sup>a</sup>(SCNA) Somatic copy number alterations.

The TNF-receptor associated factor TRAF3 is part of the CD40 signaling cascade regulating proliferation, immunoglobulin class switching, and apoptosis (Rousset et al. 1991; Tsubata et al. 1993; Kornbluth et al. 2012). TRAF3 also acts in a complex with TRAF2, BIRC2 (cIAP1), and BIRC3 (cIAP2) to target MAP3K14 (NIK) for degradation, thereby regulating the alternative NF- $\kappa$ B pathway regulating proliferation, B-cell activation, and other processes (for review, see Sun 2011). *TRAF3* alone is mutated in 30%, and either or both *TRAF3* and *MAP3K14* are mutated in 50% of the cocker spaniel B-cell lymphomas and 30% of all golden retriever B-cell lymphomas—those two genes are also commonly seen mutated in human classical Hodgkin's lymphoma (Table 1; Otto et al. 2012). A recent study, inspired by *TRAF3* mutations in canine B-cell lymphoma RNA-seq showed that *TRAF3* loss resulting in decreased gene expression is a feature of some human DLBCLs (Bushell et al. 2015). The *TRAF3* gene is also significantly mutated in multiple myeloma (Lawrence et al. 2014). *BIRC3* is mutated in mantle cell lymphoma and GCB DLBCL but not in Burkitt's lymphoma or ABC DLBCL (Zhang et al. 2014).


*FAM90A1*, the fourth most significantly mutated gene among B-cell lymphomas (16%) belongs to a gene family with 25 members in the human genome, several resulting from a primate-specific gene duplication (Bosch et al. 2007). Dogs have four paralogs, of which only one is recurrently mutated in B-cell lymphoma. The same paralog is mutated in 7% of the T-cell lymphomas. The clustering of the mutations in this gene suggests that they are functionally relevant. The exact function of this gene is unknown.

#### Mutation patterns in T-cell lymphoma predisposed breeds overlap very little

In contrast to B-cell lymphomas, the T-cell lymphoma defining genes are largely not shared between the two predisposed breeds (golden retrievers and boxers). Of the 15 most commonly mutated genes in each of the two predisposed breeds, only one is shared (*SATB1*). Of the six significantly mutated genes identified in Bx T-cell lymphomas with MuSiC analysis, only one, *SATB1*, is reported mutated among the Gr T-cell lymphoma tumors (Table 2).

Since the significantly mutated genes in the two T-cell lymphoma breeds were very different, they were analyzed separately with IPA. The respective networks are not shared. Top networks are “Cellular Development, Cellular Growth and Proliferation, Cellular Movement” for Bx T-cell and “Connective Tissue Development and Function, Tissue Morphology, Cell-To-Cell Signaling and Interaction” for Gr T-cell lymphoma (Supplemental Table S9). Similarly, functional annotation charts generated using DAVID implicates cell adhesion and cell migration for the Boxer significantly mutated genes, whereas the gene ontology terms associated with the top significantly mutated genes from Gr T-cell lymphomas mostly revolve around ribosomes and mitochondria. The canonical pathway suggested to be affected for Bx T-cell lymphomas reflect the recurrent mutations in *PTEN* and *MAP2K1*; these two genes are mutated in 38% of all Bx T-cell lymphomas and not in a single Gr T-cell lymphoma or any of the B-cell lymphomas in this study (Table 2).

Bx T-cell lymphomas were typically mutated in *SATB1* and *PTEN*. *SATB1* is a matrix protein recruiting chromatin remodeling factors, thereby regulating chromatin state and gene expression. This gene was mutated in 25% of all Bx and 12% of the Gr T-cell lymphomas. The well-known tumor suppressor gene *PTEN* is mutated in 25% of all Bx and none of the Gr T-cell lymphomas. Several human cancers show deregulation of the PI3K pathway (Samuels et al. 2004). The *PI3KCD*, *PIK3RI*, and *MTOR* genes have been reported to be mutated in occasional DLBCL cases (Zhang et al. 2013). *PTEN* antagonizes the PI3K-AKT-mTOR pathway (Maehama and Dixon 1998; for review, see Song et al. 2012; Worby and Dixon 2014), and at least one of those four genes are mutated in almost half (44%) of all Bx T-cell lymphomas but only in 6% of all Gr T-cell lymphomas (Table 2), suggesting that this pathway is highly important for Bx T-cell lymphoma development. Hypothesizing that it may be something in the genetic background of boxers that increases their likelihood of getting mutations in the *PTEN*-mTOR pathway, other important genes connected to this pathway were evaluated for germline mutations in exome-sequenced blood DNA from boxers and non-boxers, identifying a nonsynonymous variant in *FOS*. Eighty-one percent of the boxers ( $n=16$ ) are heterozygous or homozygous for the



**Figure 3.** The same amino acid in FBXW7 is recurrently mutated in human and dogs. (*Upper*) Canine FBXW7 mutations show recurrent targeting of amino acid R470. (*Lower*) A subset of the mutations reported in various human cancers (TumorPortal) (Lawrence et al. 2014) shows recurrent mutations on two amino acid positions including R465, the equivalent of canine R470.

variant, compared to 4% of the non-boxers ( $n = 210$ ). The variant, on canine Chr 8: 48333412, changes a serine to an isoleucine and is predicted to be “probably damaging” by PolyPhen-2 (Adzhubei et al. 2010). It is, however, impossible to say if this variant is linked to the detected mutation frequency in the PTEN-mTOR pathway in boxers without further analysis.

The most significantly mutated genes in Gr T-cell lymphomas are *PSMA1*, the cytochrome C oxidase subunit *COX8A*, and leukotriene A4 hydrolase (*LTA4H*). *LTA4H* and *PSMA1* have not been associated with human T-cell lymphoma, but have been associated with other human cancers (Chen et al. 2003; Onken et al. 2010; Jansen et al. 2012) and indicate new treatment options for Gr T-cell lymphoma. Proteasome subunit gene *PSMA1* is significantly mutated in both B- and T-cell lymphomas. *COX8A* is a cytochrome c oxidase subunit, which is involved in apoptosis (Liu et al. 1996). Inhibition of *LTA4H* is associated with chronic inflammation (Snelgrove et al. 2010; Wells et al. 2014), and mutations in this gene may reflect de-differentiation of the tumor, although the recurrent nature of the mutations rather suggests a gain-of-function mutation.

T-cell lymphoma tumors from both boxers and golden retrievers also have significant mutations in separate members of the *NLRP* gene family. Those two members have not previously been implicated in cancer. *NLRP5* is significantly mutated in golden retriever lymphomas, and *NLRP14* is significantly mutated in boxer lymphomas (Table 2).

## Discussion

Breeding to select for phenotypic traits in dogs has created genetic isolates (breeds) that not only present with wide morphologic variation, but also have developed differential predispositions to disease. Using different breeds, we see that the two breeds predisposed

to B-cell lymphoma have large overlaps in commonly mutated genes and pathways, whereas T-cell lymphomas from two predisposed breeds are very different. There is no population structure between those three breeds. The breeds diverged from the ancestral dog population independently and at essentially the same time (Vaysse et al. 2011), so the similarity between B-cell lymphomas cannot be explained by higher relatedness between the predisposed breeds. In particular, the B-cell lymphomas are strikingly similar to human B-cell lymphomas. We see recurrent mutations affecting NF- $\kappa$ B signaling and histone modifiers, both of which are typically seen in human DLBCL. The two T-cell lymphoma breeds typically develop different types of T-cell tumors, and their mutation patterns are more different. This raises the possibility that genetic background predisposes to different subtypes of T-cell lymphoma and may help dissect the genetic underpinnings of different T-cell types. It is therefore important to understand which human lymphoma subtypes the lymphomas in different breeds are most similar to.

The difference in mutation pattern between T-cell lymphomas from boxers and golden retrievers is particularly interesting. Boxers often develop lymphoblastic T-cell lymphomas as well as peripheral T-cell lymphoma (PTCL) (Lurie et al. 2008), both aggressive forms of T-cell lymphoma (Frantz et al. 2013), whereas golden retrievers are more prone to developing T-zone lymphomas that are relatively mild and have not been described in humans (Fosmire et al. 2007; Seelig et al. 2014). The typical mutation pattern in those two breeds is remarkably distinct. Due to the number of different subtypes present in each breed and the number of individuals without subtype information available in this study, it is impossible to say whether the genetic differences between subtypes are smaller or larger than the genetic difference between tumors from different breeds (Supplemental Material). Further studies are required to determine if somatic mutations reflect the

subtype, which has a genetic predisposing component, or if somatic mutations directly reflect genetic background, or a combination thereof. The mutations in PTEN-mTOR pathway in half (44%) of all Bx T-cell lymphomas suggest that this pathway is highly important for the formation of aggressive lymphomas. In human cancers, *PTEN* is most commonly lost in endometrial cancer and glioblastoma (Lawrence et al. 2014). Uterine cancers are generally uncommon among all US dogs due to spaying practices, but boxers have an increased frequency of glioma. It can be speculated that boxers may be “predisposed” for a mutation in this pathway—that is, that their genetic background gives them an increased sensitivity for such mutations. Interestingly, 81% of all the boxers sequenced here carry a germline variant in *FOS*. Only 4% of the exome-sequenced non-boxer dogs ( $n=210$ ) carry this variant. As the *FOS* transcription factor controls some of the same downstream targets of the PTEN-mTOR pathway (Koul et al. 2007; De Marco et al. 2013), it is possible that the genetic background of a boxer could make them more sensitive to a mutation in the PTEN-mTOR pathway in relevant cell types compared to the average dog. It has been shown that genetic background predisposes to specific cancers, even specific lymphoma subtypes. This could happen through the genetic background making the individual more sensitive to mutations in specific cancer genes that determine disease subtype. Genetic background also affects overall tumor mutation load, as evident from the lower somatic mutation frequency in golden retrievers compared with the two other breeds.

The B-cell lymphomas may also be subdivided based on their mutation profile. *TRAF3-TRAF2-BIRC2-BIRC3-MAP3K14* are mutated in 30% of all B-cell lymphomas, and 50% of all Cs B-cell lymphomas, which is about the same fraction as human DLBCL tumors with dysregulated canonical or noncanonical NF- $\kappa$ B pathways (Compagno et al. 2009). In contrast to the T-cell lymphomas, we see very few differences in significantly mutated genes between B-cell lymphomas for the two studied breeds. This certainly reflects a more uniform mutation pattern, but it is possible that there are subtle differences between the two breeds that we do not pick up because of the relatively low number of cocker spaniel samples included in this study. For example, *FBXW7* appears to be more recurrently mutated in B-cell lymphomas from golden retriever compared to cocker spaniels, but this difference is not statistically significant.

The recurrent mutations in specific genes and pathways are likely reflecting the relatively homogeneous genetic background of each breed, allowing us to identify molecular subtypes based on genetic background. Such genetic backgrounds may be exemplified by the two loci predisposing to B-cell lymphoma and hemangiosarcoma in golden retrievers (found by genome-wide association mapping), which are associated with differential expression of immune-related genes, including *BIRC3* (Tonomura et al. 2015). These results point to a mechanism involving altered T-cell activation as a strong predisposing factor in this breed. All three breeds analyzed here for lymphoma tumor mutation also have an increased incidence of autoimmune disorders like atopic dermatitis. The risk of developing several lymphoma subtypes, including DLBCL, is elevated in patients with autoimmune diseases like Sjögren’s syndrome and SLE (lupus) (Smedby et al. 2006). This could suggest that the lymphoma predisposition in the breeds comes from an unbalanced immune regulation.

Several of the recurrently mutated genes have not previously been implicated in human lymphoma, including *NLRP5*, *NLRP14*, and *GRIFIN*. This follows the pattern reported previously in hu-

man studies, suggesting that the majority of mutations specific to certain cancer subtypes or relatively rare mutations have not yet been reported (Lawrence et al. 2014). Those novel mutations, and mutations reported in other cancers but not lymphoma, may indicate novel treatment possibilities in lymphoma. Generally, the same chemotherapeutic agents are effective in both dogs and humans (Honigberg et al. 2010; London et al. 2014). Hence, it is highly likely that the significantly mutated genes identified in dogs are suggestive of genes and pathways involved in human lymphoma, possibly allowing new treatment options. Several of the most significantly mutated genes in dogs, such as *MITF*, *FKBP3*, and *LTA4H*, have been identified in a small proportion of human lymphoma cases, suggesting that the homogeneous genetic background of dog breeds may highlight mutations important for, and possibly guiding treatment for, a subset of human patients.

Looking at the most significantly mutated genes in B-cell and T-cell lymphomas across the three studied breeds, genes not previously implicated in human lymphoma include well-known cancer-associated genes such as *LTA4H* and *PSMA1*, indicating potential treatment with proteasome inhibitors. In contrast, *TBC1D26* is a novel cancer gene, which may allow for completely new treatments. *TBC1D26* has not been well characterized, but belongs to a family of proteins in which other members have been implicated in cell cycle control. *TBC1D26* paralogs are mutated in 17% of all samples, with the *ENSCAFG00000025100* paralog being the most commonly mutated, and the mutations cluster in a few domains. Additionally, each T-cell lymphoma predisposed breed is significantly mutated in a different member of the *NLRP* gene family, which is primarily associated with a role in innate immunity (Pedraza-Alva et al. 2015) as well as reproduction (Duéñez-Guzmán and Haig 2014).

Canine studies may be more translational at the pathway level than at the gene level for example histone acetyltransferases and methyltransferases are recurrently mutated in human lymphomas; and although the exact genes only partially overlap, other histone modifiers are mutated in the dog. This affirms the observation that the mechanisms of lymphoma overlap strongly between humans and dogs.

In conclusion, our results highlight how the spontaneously occurring lymphomas in purebred dogs can be very helpful in characterizing different tumor molecular subtypes, which should contribute to the understanding of both canine and human lymphomas.

## Methods

### Sample collection

Tissue samples (lymph node with tumor and matched blood or healthy lymph node) were provided by coauthors, veterinary hospitals, or obtained from the Pfizer Canine Comparative Oncology and Genomics Consortium (CCOGC) Biospecimen Repository. Investigators at other institutions may have received specimens from the same subjects from CCOGC. Naïve (newly diagnosed and untreated) disease was one of the eligibility criteria for participation. For lymph node details, see Supplemental Material.

### Immunophenotyping

Immunophenotyping information was supplied with the samples, or determined by immunohistochemistry using CD3/CD79A markers, or by PARR (Burnett et al. 2003). Subtyping information (DLBCL, TZL, PTCL, etc.) was only available for one-third of the

samples and hence not considered for the analysis (see Supplemental Material).

### Library construction and sequencing

Dog exome libraries were generated from standard indexed Illumina libraries using a custom Roche/Nimblegen solution-based capture library (120705\_CF3\_Uppsala\_Broad\_EZ\_HX1) following the protocol provided. The libraries capture 85% of the canine exonic regions. Per suggestion from Nimblegen, developer's reagent (06684335001) was used in place of COT-1. Index-specific hybridization enhancing oligos were used.

### Alignment and filtering

After capture, tumor and normal indexed libraries were pooled separately into groups of eight. All pools were run on an Illumina HiSeq 2000 platform, with coverage targets of 30× for normal pools and 60× for tumor pools.

The reads were aligned to the CanFam3.1 reference genome (Hoeppner et al. 2014) using BWA 0.5.9 (Li and Durbin 2009). Using the Picard tool kit (<http://broadinstitute.github.io/picard/>), the duplicate reads were marked, and the data were sorted. Using the Genome Analysis Toolkit (GATK) software, local realignments were generated with cocleaning of tumor/normal sample pairs, and base quality scores were recalibrated per GATK Best Practices (Van der Auwera et al. 2013). Samples with fewer than 50% of target bases covered to 10× were removed.

### Variant calling

GATK 2.6 (DePristo et al. 2011) was used to realign the reads around indels. MuTect 1.1.4 (<http://www.broadinstitute.org/cancer/cga/mutect>) and Indelocator (<http://www.broadinstitute.org/cancer/cga/indelocator>) were used to call SNPs and indels, respectively, on the resulting BAM files. Samples with more than 5 SD more variants than the mean were removed since this may reflect incorrect pairing of tumor and normal DNA. MuTect uses a statistical model to determine the likelihoods based on the reads of a position being at least partially nonreference in tumor and of being homozygous reference in normal. If these likelihoods are high enough, it concludes that a somatic event has happened. Variants considered by these programs to be somatic rather than germline were retained, and SnpEff 3.3 (Cingolani et al. 2012) was used to predict the possible effects of these variants. Although SnpEff reports all possible effects of a particular variant, we retained only one effect for each variant, choosing that which was judged to be most impactful. The resulting VCF files were compiled into a single MAF file using custom code.

### Variant filtering

The somatic variants were filtered to remove false positives due to germline population variation. This was done in two steps: First, previously known population variation was removed from the somatic set (Lindblad-Toh et al. 2005; Vaysse et al. 2011; Axelsson et al. 2013) and supplemented with additional variants identified by Erik Axelsson (E Axelsson and K Lindblad-Toh, unpubl.). Second, variants were removed that were found to be present in a panel of normal canine samples. Variants in these normal samples were called using SAMtools 1.1 and BCftools 1.1 (<http://www.htslib.org/>). Normal variants were considered "true" if the Phred-scaled likelihood score of being homozygous reference at that position was greater than 50, meaning, if it was sufficiently likely that at least one allele was variant. The variant was "trusted" if the same variant was true in two or more samples. Indels could

additionally be considered trusted if two or more indels were found to be true at that position (including the indel in question). All trusted variants were filtered out of the MuTect output files. Subsequently, putatively somatic variants within immunoglobulin genes and T-cell receptors (where variation is likely not reflecting the tumor) and those in olfactory receptors were removed. Finally, the top 25 significantly mutated genes from each breed group were scored for recurrent mutations. These were evaluated manually in IGV (Thorvaldsdóttir et al. 2012) and removed if the variant was considered highly likely to be a false positive, for example, because of read alignment problems due to insufficient cocleaning or if the vast majority of variants were supported by reads whose mate aligned to another chromosome with strong similarity to this region.

### Significantly mutated genes

The filtered mutation file, along with the original BAM files and Ensembl's dog annotation v.75 (Hoeppner et al. 2014) were run through Genome MuSiC 0.4 (Dees et al. 2012) to produce a list of significantly mutated genes. Default settings were used, except if multiple mutations were seen in a gene in one individual, they were counted as one ("merge concurrent" option). Multiple mutations in a gene could reflect mutations in different subclones, mutations in both gene copies in one cell, or several mutations targeting function, but it could also arise from lower purifying selective pressure on a gene whose function was already lost.

### Pathway analysis

Ingenuity pathway analysis (<http://www.ingenuity.com>) was used for pathway analysis using standard settings. Human gene names and MuSiC CT *P*-values were used. For analysis using DAVID (Huang da et al. 2009a,b), the top 15 (or all, if less than 15) significantly mutated genes were inputted as "gene list."

### SCNA

Somatic copy number alterations were estimated from exome data by adapting the SegSeq algorithm (Chiang et al. 2009). Only 40 dogs could be used due to a recurrent artifact pattern, hence, all samples were analyzed together. DNA segments subject to somatic copy number alterations were analyzed with GISTIC 2.0 (Mermel et al. 2011).

### Data access

The sequence data from this study have been submitted to the NCBI Sequence Read Archive (SRA; <http://www.ncbi.nlm.nih.gov/sra/>). Accession numbers are listed in Supplemental Table S10. Somatic and germline variants have been deposited in NCBI dbSNP (<http://www.ncbi.nlm.nih.gov/SNP/>) under the assay IDs (ss#) listed in the Supplemental Material, and have been integrated into the "Broad Improved Canine Annotation v1" track hub at the UCSC Genome Browser (<http://genome.ucsc.edu/cgi-bin/hgHubConnect>). The tracks are called "Lymphoma som SNPs" and "Germline PON SNPs," respectively.

### Competing interest statement

A patent (BI-2014/089 - B1195.70034US00) has been filed.

## Acknowledgments

We thank all dogs and their owners for their help and support, Leslie Gaffney for help with illustrations, the Broad Institute Genomics platform for sequencing, and the Breen laboratory and Dr. Daisuke Ito for immunophenotyping. Funding is gratefully acknowledged from the National Institutes of Health (U54 HG003067-08, awarded to the Broad Institute), the European Research Council (ERC), the American Kennel Club (AKC) Canine Health Foundation, the Golden Retriever Foundation, and the Morris Animal Foundation. I.E. is supported by a postdoctoral fellowship from the Swedish Medical Research Council. K.L.-T. is the recipient of a EURYI award from the ESF and an ERC Consolidator Award from the ERC. J.F.M. is supported in part by the Alvin S. and June Perlman Chair in Animal Oncology at the University of Minnesota.

## References

- Abramson JS, Shipp MA. 2005. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. *Blood* **106**: 1164–1174.
- Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. 2010. A method and server for predicting damaging missense mutations. *Nat Methods* **7**: 248–249.
- Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature* **403**: 503–511.
- Axelsson E, Ratnakumar A, Arendt ML, Maqbool K, Webster MT, Perloski M, Liberg O, Arnemo JM, Hedhammar A, Lindblad-Toh K. 2013. The genomic signature of dog domestication reveals adaptation to a starch-rich diet. *Nature* **495**: 360–364.
- Bellon M, Datta A, Brown M, Pouliquen JF, Couppie P, Kazanji M, Nicot C. 2006. Increased expression of telomere length regulating factors TRF1, TRF2 and TIN2 in patients with adult T-cell leukemia. *Int J Cancer* **119**: 2090–2097.
- Bosch N, Cáceres M, Cardone MF, Carreras A, Ballana E, Rocchi M, Armengol L, Estivill X. 2007. Characterization and evolution of the novel gene family *FAM90A* in primates originated by multiple duplication and rearrangement events. *Hum Mol Genet* **16**: 2572–2582.
- Burnett RC, Vernau W, Modiano JF, Olver CS, Moore PF, Avery AC. 2003. Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes. *Vet Pathol* **40**: 32–41.
- Bushell KR, Kim Y, Chan FC, Ben-Neriah S, Jenks A, Alcaide M, Fornika D, Grande BM, Arthur S, Gascoyne RD, et al. 2015. Genetic inactivation of *TRAF3* in canine and human B-cell lymphoma. *Blood* **125**: 999–1005.
- Chen X, Li N, Wang S, Wu N, Hong J, Jiao X, Krasna MJ, Beer DG, Yang CS. 2003. Leukotriene A<sub>4</sub> hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin. *J Natl Cancer Inst* **95**: 1053–1061.
- Chiang DY, Getz G, Jaffe DB, O'Kelly MJ, Zhao X, Carter SL, Russ C, Nusbaum C, Meyerson M, Lander ES. 2009. High-resolution mapping of copy-number alterations with massively parallel sequencing. *Nat Methods* **6**: 99–103.
- Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES, Getz G. 2013. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. *Nat Biotechnol* **31**: 213–219.
- Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, Land SJ, Lu X, Ruden DM. 2012. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster* strain *w<sup>1118</sup>*; *iso-2*; *iso-3*. *Fly (Austin)* **6**: 80–92.
- Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A, et al. 2009. Mutations of multiple genes cause deregulation of NF- $\kappa$ B in diffuse large B-cell lymphoma. *Nature* **459**: 717–721.
- Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, et al. 2010. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. *Nature* **463**: 88–92.
- De Marco C, Rinaldo N, Bruni P, Malzoni C, Zullo F, Fabiani F, Losito S, Scrima M, Marino FZ, Franco R, et al. 2013. Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma. *PLoS One* **8**: e55362.
- Dees ND, Zhang Q, Kandath DC, Wendt MC, Schierding W, Koboldt DC, Mooney TB, Callaway MB, Dooling D, Mardis ER, et al. 2012. MuSiC: identifying mutational significance in cancer genomes. *Genome Res* **22**: 1589–1598.
- DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M, et al. 2011. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet* **43**: 491–498.
- Dobson JM, Blackwood LB, McInnes EF, Bostock DE, Nicholls P, Hoather TM, Tom BD. 2001. Prognostic variables in canine multicentric lymphosarcoma. *J Small Anim Pract* **42**: 377–384.
- Dodman NH, Karlsson EK, Moon-Fanelli A, Galdzicka M, Perloski M, Shuster L, Lindblad-Toh K, Ginns EI. 2010. A canine chromosome 7 locus confers compulsive disorder susceptibility. *Mol Psychiatry* **15**: 8–10.
- Duñéz-Guzmán EA, Haig D. 2014. The evolution of reproduction-related *NLRP* genes. *J Mol Evol* **78**: 194–201.
- Evens AM, Gartenhaus RB. 2003. Molecular etiology of mature T-cell non-Hodgkin's lymphomas. *Front Biosci* **8**: d156–d175.
- Fosmire SP, Thomas R, Jubala CM, Wojcieszyn JW, Valli VE, Getzy DM, Smith TL, Gardner LA, Ritt MG, Bell JS, et al. 2007. Inactivation of the p16 cyclin-dependent kinase inhibitor in high-grade canine non-Hodgkin's T-cell lymphoma. *Vet Pathol* **44**: 467–478.
- Frantz AM, Sarver AL, Ito D, Phang TL, Karimpour-Fard A, Scott MC, Valli VE, Lindblad-Toh K, Burgess KE, Husbands BD, et al. 2013. Molecular profiling reveals prognostically significant subtypes of canine lymphoma. *Vet Pathol* **50**: 693–703.
- Glickman L, Glickman N, Thorpe R. 2000. The Golden Retriever Club of America National Health Survey 1998–1999. Purdue University School of Veterinary Medicine, West Lafayette, IN. <http://www.grca.org/pdf/health/healthsurvey.pdf>.
- Gonzalez-Aguilar A, Idbah A, Boisselier B, Habbita N, Rossetto M, Laurence A, Bruno A, Jouve A, Polivka M, Adam C, et al. 2012. Recurrent mutations of *MYD88* and *TBL1XR1* in primary central nervous system lymphomas. *Clin Cancer Res* **18**: 5203–5211.
- Hoepfner MP, Lundquist A, Pirun M, Meadows JR, Zamani N, Johnson J, Sundström G, Cook A, FitzGerald MG, Swofford R, et al. 2014. An improved canine genome and a comprehensive catalogue of coding genes and non-coding transcripts. *PLoS One* **9**: e91172.
- Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, et al. 2010. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. *Proc Natl Acad Sci* **107**: 13075–13080.
- Huang da W, Sherman BT, Lempicki RA. 2009a. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res* **37**: 1–13.
- Huang da W, Sherman BT, Lempicki RA. 2009b. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* **4**: 44–57.
- Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C, Geng H, Deffenbacher K, Smith L, Dybkaer K, et al. 2010. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. *Blood* **115**: 1026–1036.
- Ito D, Frantz AM, Modiano JF. 2014. Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications. *Vet Immunol Immunopathol* **159**: 192–201.
- Jansen FH, van Rijswijk A, Teubel W, van Weerden WM, Reneman S, van den Bemd GJ, Roobol MJ, Bangma CH, Staal FJ, Jenster G. 2012. Profiling of antibody production against xenograft-released proteins by protein microarrays discovers prostate cancer markers. *J Proteome Res* **11**: 728–735.
- Karlsson EK, Sigurdsson S, Ivansson E, Thomas R, Elvers I, Wright J, Howald C, Tonomura N, Perloski M, Swofford R, et al. 2013. Genome-wide analyses implicate 33 loci in heritable dog osteosarcoma, including regulatory variants near *CDKN2A/B*. *Genome Biol* **14**: R132.
- Koepp DM, Schaefer LK, Ye X, Keyomarsi K, Chu C, Harper JW, Elledge SJ. 2001. Phosphorylation-dependent ubiquitination of cyclin E by the SCF<sup>Fbw7</sup> ubiquitin ligase. *Science* **294**: 173–177.
- Kornbluth RS, Stempniak M, Stone GW. 2012. Design of CD40 agonists and their use in growing B cells for cancer immunotherapy. *Int Rev Immunol* **31**: 279–288.
- Koul D, Shen R, Shishodia S, Takada Y, Bhat KP, Reddy SA, Aggarwal BB, Yung WK. 2007. PTEN down regulates AP-1 and targets *c-fos* in human glioma cells via PI3-kinase/Akt pathway. *Mol Cell Biochem* **300**: 77–87.
- Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G. 2014. Discovery and saturation analysis of cancer genes across 21 tumour types. *Nature* **505**: 495–501.
- Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, Dave SS, Zhao H, Xu W, Rosenwald A, et al. 2008. Oncogenic *CARD11* mutations in human diffuse large B cell lymphoma. *Science* **319**: 1676–1679.

- Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows–Wheeler transform. *Bioinformatics* **25**: 1754–1760.
- Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M, Clamp M, Chang JL, Kulbokas EJ III, Zody MC, et al. 2005. Genome sequence, comparative analysis and haplotype structure of the domestic dog. *Nature* **438**: 803–819.
- Liu X, Kim CN, Yang J, Jemmerson R, Wang X. 1996. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. *Cell* **86**: 147–157.
- Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, Cruz-Gordillo P, Knoechel B, Asmann YW, Slager SL, et al. 2012. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. *Proc Natl Acad Sci* **109**: 3879–3884.
- London CA, Bernabe LF, Barnard S, Kisseberth WC, Borgatti A, Henson M, Wilson H, Jensen K, Ito D, Modiano JF, et al. 2014. Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study. *PLoS One* **9**: e87585.
- Lurie DM, Milner RJ, Suter SE, Vernau W. 2008. Immunophenotypic and cytomorphic subclassification of T-cell lymphoma in the boxer breed. *Vet Immunol Immunopathol* **125**: 102–110.
- Maehama T, Dixon JE. 1998. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. *J Biol Chem* **273**: 13375–13378.
- Mandelbaum J, Bhagat G, Tang H, Mo T, Brahmachary M, Shen Q, Chadburn A, Rajewsky K, Tarakhovskiy A, Pasqualucci L, et al. 2010. *BLIMP1* is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. *Cancer Cell* **18**: 568–579.
- Marconato L, Gelain ME, Comazzi S. 2013. The dog as a possible animal model for human non-Hodgkin lymphoma: a review. *Hematol Oncol* **31**: 1–9.
- Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhir R, Getz G. 2011. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. *Genome Biol* **12**: R41.
- Modiano JF, Breen M, Burnett RC, Parker HG, Inusah S, Thomas R, Avery PR, Lindblad-Toh K, Ostrander EA, Cutter GC, et al. 2005. Distinct B-cell and T-cell lymphoproliferative disease prevalence among dog breeds indicates heritable risk. *Cancer Res* **65**: 5654–5661.
- Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer F, et al. 2010. Somatic mutations altering *EZH2* (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. *Nat Genet* **42**: 181–185.
- Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, et al. 2011. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. *Nature* **476**: 298–303.
- Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, et al. 2011. Oncogenically active *MYD88* mutations in human lymphoma. *Nature* **470**: 115–119.
- Onishi Y, Kawamoto T, Kishimoto K, Hara H, Fukase N, Toda M, Harada R, Kurosaka M, Akisue T. 2012. *PKD1* negatively regulates cell invasion, migration and proliferation ability of human osteosarcoma. *Int J Oncol* **40**: 1839–1848.
- Onken MD, Worley LA, Tuscan MD, Harbour JW. 2010. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. *J Mol Diagn* **12**: 461–468.
- Otto C, Giefing M, Massow A, Vater I, Gesk S, Schlesner M, Richter J, Klapper W, Hansmann ML, Siebert R, et al. 2012. Genetic lesions of the *TRAF3* and *MAP3K14* genes in classical Hodgkin lymphoma. *Br J Haematol* **157**: 702–708.
- Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, Kasper LH, Lerach S, Tang H, Ma J, et al. 2011a. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. *Nature* **471**: 189–195.
- Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, Wells VA, Grunn A, Messina M, Elliot O, et al. 2011b. Analysis of the coding genome of diffuse large B-cell lymphoma. *Nat Genet* **43**: 830–837.
- Pastor M, Chalvet-Monfray K, Marchal T, Keck G, Magnol JP, Fournel-Flcury C, Ponce F. 2009. Genetic and environmental risk indicators in canine non-Hodgkin's lymphomas: breed associations and geographic distribution of 608 cases diagnosed throughout France over 1 year. *J Vet Intern Med* **23**: 301–310.
- Pedraza-Alva G, Pérez-Martínez L, Valdez-Hernández L, Meza-Sosa KF, Ando-Kuri M. 2015. Negative regulation of the inflammasome: keeping inflammation under control. *Immunol Rev* **265**: 231–257.
- Ponce F, Marchal T, Magnol JP, Turinelli V, Ledieu D, Bonnefont C, Pastor M, Delignette ML, Fournel-Flcury C. 2010. A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology. *Vet Pathol* **47**: 414–433.
- Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, Meissner B, Bhargava HE, Ruddy D, Kauffmann A, et al. 2014. Pharmacological and genomic profiling identifies NF- $\kappa$ B-targeted treatment strategies for mantle cell lymphoma. *Nat Med* **20**: 87–92.
- Richards KL, Motsinger-Reif AA, Chen HW, Fedoriv Y, Fan C, Nielsen DM, Small GW, Thomas R, Smith C, Dave SS, et al. 2013. Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL. *Cancer Res* **73**: 5029–5039.
- Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B, Rosolowski M, Ammerpohl O, Wagener R, Bernhart SH, et al. 2012. Recurrent mutation of the *ID3* gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. *Nat Genet* **44**: 1316–1320.
- Robles-Espinoza CD, Harland M, Ramsay AJ, Aoude LG, Quesada V, Ding Z, Pooley KA, Pritchard AL, Tiffen JC, Petljak M, et al. 2014. *POT1* loss-of-function variants predispose to familial melanoma. *Nature Genet* **46**: 478–481.
- Rousset F, Garcia E, Banchereau J. 1991. Cytokine-induced proliferation and immunoglobulin production of human B lymphocytes triggered through their CD40 antigen. *J Exp Med* **173**: 705–710.
- Ruslander DA, Gebhard DH, Tompkins MB, Grindem CB, Page RL. 1997. Immunophenotypic characterization of canine lymphoproliferative disorders. *In Vivo* **11**: 169–172.
- Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, et al. 2004. High frequency of mutations of the *PIK3CA* gene in human cancers. *Science* **304**: 554.
- Seelig DM, Avery P, Webb T, Yoshimoto J, Bromberek J, Ehrhart EJ, Avery AC. 2014. Canine T-zone lymphoma: unique immunophenotypic features, outcome, and population characteristics. *J Vet Intern Med* **28**: 878–886.
- Shearin AL, Hedan B, Cadieu E, Erich SA, Schmidt EV, Faden DL, Cullen J, Abadie J, Kwon EM, Grone A, et al. 2012. The *MTAP-CDKN2A* locus confers susceptibility to a naturally occurring canine cancer. *Cancer Epidemiol Biomarkers Prev* **21**: 1019–1027.
- Shi J, Yang XR, Ballew B, Rotunno M, Callista D, Fargnoli MC, Ghiorzo P, Bressac-de Paillerets B, Nagore E, Avril MF, et al. 2014. Rare missense variants in *POT1* predispose to familial cutaneous malignant melanoma. *Nat Genet* **46**: 482–486.
- Smedby KE, Hjalgrim H, Askling J, Chang ET, Gregersen H, Porwit-MacDonald A, Sundström C, Åkerman M, Melbye M, Glimelius B, et al. 2006. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. *J Natl Cancer Inst* **98**: 51–60.
- Snelgrove RJ, Jackson PL, Hardison MT, Noerager BD, Kinloch A, Gaggari A, Shastry S, Rowe SM, Shim YM, Hussell T, et al. 2010. A critical role for LTA<sub>4</sub>H in limiting chronic pulmonary neutrophilic inflammation. *Science* **330**: 90–94.
- Song MS, Salmena L, Pandolfi PP. 2012. The functions and regulation of the PTEN tumour suppressor. *Nat Rev Mol Cell Biol* **13**: 283–296.
- Sun SC. 2011. Non-canonical NF- $\kappa$ B signaling pathway. *Cell Res* **21**: 71–85.
- Tang R, Noh H, Wang D, Sigurdsson S, Swofford R, Perloski M, Duxbury M, Patterson EE, Albright J, Castelano M, et al. 2014. Candidate genes and functional noncoding variants identified in a canine model of obsessive-compulsive disorder. *Genome Biol* **15**: R25.
- Thorvaldsdóttir H, Robinson JT, Mesirov JP. 2012. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. *Brief Bioinform* **14**: 178–192.
- Tonomura N, Elvers I, Thomas R, Megquier K, Turner-Maier J, Howald C, Sarver AL, Swofford R, Frantz AM, Ito D, et al. 2015. Genome-wide association study identifies shared risk loci common to two malignancies in golden retrievers. *PLoS Genet* **11**: e1004922.
- Tsubata T, Wu J, Honjo T. 1993. B-cell apoptosis induced by antigen receptor crosslinking is blocked by a T-cell signal through CD40. *Nature* **364**: 645–648.
- Vaill DM, MacEwen EG. 2000. Spontaneously occurring tumors of companion animals as models for human cancer. *Cancer Invest* **18**: 781–792.
- Valli VE, San Myint M, Barthel A, Bienze D, Caswell J, Colbatzky F, Durham A, Ehrhart EJ, Johnson Y, Jones C, et al. 2011. Classification of canine malignant lymphomas according to the World Health Organization criteria. *Vet Pathol* **48**: 198–211.
- Valli VE, Kass PH, San Myint M, Scott F. 2013. Canine lymphomas: association of classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival. *Vet Pathol* **50**: 738–748.
- Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, Jordan T, Shakir K, Roazen D, Thibault J, et al. 2013. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. *Curr Protoc Bioinformatics* **11**: 11.10.1–11.10.33.

- Vaysse A, Ratnakumar A, Derrien T, Axelsson E, Rosengren Pielberg G, Sigurdsson S, Fall T, Seppälä EH, Hansen MS, Lawley CT, et al. 2011. Identification of genomic regions associated with phenotypic variation between dog breeds using selection mapping. *PLoS Genet* **7**: e1002316.
- Vega F, Cho-Vega JH, Lennon PA, Luthra MG, Bailey J, Breeden M, Jones D, Medeiros LJ, Luthra R. 2008. Splenic marginal zone lymphomas are characterized by loss of interstitial regions of chromosome 7q, 7q31.32 and 7q36.2 that include the protection of telomere 1 (*POT1*) and sonic hedgehog (*SHH*) genes. *Br J Haematol* **142**: 216–226.
- Wells JM, O'Reilly PJ, Szul T, Sullivan DI, Handley G, Garrett C, McNicholas CM, Roda MA, Miller BE, Tal-Singer R, et al. 2014. An aberrant leukotriene A4 hydrolase-proline-glycine-proline pathway in the pathogenesis of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* **190**: 51–61.
- Wilbe M, Jokinen P, Truvé K, Seppala EH, Karlsson EK, Biagi T, Hughes A, Bannasch D, Andersson G, Hansson-Hamlin H, et al. 2010. Genome-wide association mapping identifies multiple loci for a canine SLE-related disease complex. *Nat Genet* **42**: 250–254.
- Worby CA, Dixon JE. 2014. PTEN. *Annu Rev Biochem* **83**: 641–669.
- Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K, Nakayama KI. 2004. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. *EMBO J* **23**: 2116–2125.
- Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au WY, Srivastava G, et al. 2013. Genetic heterogeneity of diffuse large B-cell lymphoma. *Proc Natl Acad Sci* **110**: 1398–1403.
- Zhang J, Jima D, Moffitt AB, Liu Q, Czader M, Hsi ED, Fedoriw Y, Dunphy CH, Richards KL, Gill JI, et al. 2014. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. *Blood* **123**: 2988–2996.

Received May 13, 2015; accepted in revised form September 16, 2015.